It’s Off to the Races for eRace Cancer’s 78-year-old Founder and Multiple Myeloma Survivor
In 2003, Don Wright received a daunting diagnosis of multiple myeloma. But not only has the 78-year-old survived, he has thrived. He’s since run 100…
News
Ninlaro Maintenance Delays Disease Progression, Death in Myeloma Patients, Phase 3 Trial Shows
Multiple myeloma patients who receive Ninlaro (ixazomib) maintenance after responding to their initial treatment live longer without their disease worsening or returning than patients…
International Myeloma Foundation Gears Up for March, Myeloma Action Month
To raise awareness of multiple myeloma and efforts to cure it, the International Myeloma Foundation (IMF) is gearing up for the start of Myeloma…
Multiple Myeloma Research Foundation Makes Changes in Leadership to Advance Precision Medicine
The Multiple Myeloma Research Foundation (MMRF) is growing and adjusting its executive team, with a focus on improving multiple myeloma patient outcomes and advancing…
Partners to Develop and Market TNB-383B Antibody for Multiple Myeloma
The development and commercialization of TNB-383B — an anti-BCMA antibody for the potential treatment of multiple myeloma — is being advanced as part of a new…
Split Dosing of Darzalex Over Consecutive Days Approved by FDA for Multiple Myeloma Patients
The U.S. Food and Drug Administration has approved a new dosing regimen for the multiple myeloma treatment Darzalex (daratumumab), allowing doctors to split the first…
$75M Gift to Establish Center for Blood Cancers at NYU Langone Health Center
Owing to an anonymous $75 million gift, New York University (NYU) Langone Health and its Laura and Isaac Perlmutter Cancer Center will establish…
Real-world Data Supports Use of Oral Triple Combination in Treating Advanced Multiple Myeloma, Study Finds
Real world data from multiple myeloma patients in Hungary supports the use of a triple combination regimen — Ninlaro (ixazomib), Revlimid (lenalidomide), and…
Isatuximab Extends Time Without Cancer Progression in Phase 3 Trial of Multiple Myeloma
Adding isatuximab to a standard of care treatment of Pomalyst (pomalidomide) and low-dose dexamethasone prolonged the time without cancer progression in adults with relapsed…
Thalidomide at 100 mg Shows Benefits as Maintenance Therapy in Multiple Myeloma Patients in Trial
A maintenance treatment with thalidomide at 100 mg a day was safe and seen to delay disease progression by more than three years in multiple myeloma…
